Table 1.

Summary of public gene expression-based discovery and validation data sets used in the meta-analysis.

Disease category	Accession#	Reference	Cases	n cases	n control	Total samples	Platform
Discovery
ICUAW	GSE13205	Fredriksson49	Sepsis MODS	13	8	21	GPL570
ICUAW	GSE53702	Langhans50	ICUAW	7	6	13	GPL5188
ICUAW	GSE3307	Bakay51	ICUAW	5	13c	18c	GPL96
Congenital	GSE15090	Arashiro52	FSHD	5	5	10	GPL570
Congenital	GSE18715	Voets a	POLG1	6	12	18	GPL570
Congenital	GSE36398ab	Rahimov53	FSHD	8	16	24	GPL6244
Congenital	GSE36398b	Rahimov53	FSHD	10	8	18	GPL6244
Congenital	GSE37084	Perfetti54	MMD	10	10	20	GPL5175
Congenital	GSE26852	Tasca55	FSHD, dysferlinopathy	12	7	19	GPL6947
Congenital	GSE47968	Nakamori56	FSHD, DM	23	8	31	GPL5188
Congenital	GSE42806	Screen57	TMD	7	5	12	GPL570
Congenital	GSE38417	Dorsey a	DMD	16	6	22	GPL570
Congenital	GSE38680b	Palermo58	GSD II	9	10	19	GPL570
Congenital	GSE11681	Saenz59	LGMD2A	10	10	20	GPL96
Congenital	GSE12648	Eisenberg60	HIBM	10	10	20	GPL96
Congenital	GSE6011	Pescatori61	DMD	23	14	37	GPL96
IM	GSE48280	Surez-Calvet62	PM, IBM, DM	14	5	19	GPL6244
IM	GSE3307	Bakay51	Juvenile DM	21	13c	34c	GPL96
IM	GSE1551	Greenberg63	DM	13	10	23	GPL96
IM	GSE26852	Tasca55	PM, IM, DM	7	7	14	GPL6947
IM	EMEXP2681	Bernasconi a	DM, PM	8	7	15	GPL96
Immobility	GSE45745	Barres64	Morbid obesity	5	6	11	GPL13667
Immobility	GSE21496	Reich65	Unloading	7	7	14	GPL570
Immobility	GSE5110	Urso66	Immobility	5	5	10	GPL570
Immobility	GSE24215	Alibegovic67	Immobility	12	12	24	GPL6480
Immobility	GSE104999	Rullman68	Immobility	12	12	24	GPL17692
Immobility	GSE474	Park69	Morbid obesity	16	8	24	GPL96
Chronic	GSE27536	Turan70	COPD	30	24	54	GPL570
Chronic	GSE1786	Radom-Aizik71	COPD	12	12	24	GPL96
Chronic	EMTAB3671	Kreiner72	PMR	12	12	24	GPL570
Total				348	288	636
Validation
ICUAW	GSE78929	Walsh8	ICUAW	24	8	32	GPL10558
Congenital	GSE13608	Bachinksi73	DMD, MMD	59	9	68	GPL570
Congenital	GSE38680a	Palermo58	GSD II	32	7	39	GPL570
Congenital	GSE109178	Dadgar9	MD	42	6	48	GPL570
Congenital	GSE3307	Bakay51	MD	66	13c	79c	GPL570
Congenital	GSE10760	Osborne74	FSHD	38	60	98	GPL96
IM	GSE3112	Greenberg75	PM, IBM	29	11	40	GPL96
IM	GSE39454	Zhu76	PM, IBM, NM	31	5	36	GPL570
Immobility	GSE14901	Abadi30	Limb disuse (casting)	48	24	72	GPL570
Immobility	GSE45462	Chen77	Limb disuse (casting)	16	16	32	GPL570
Chronic	GSE34111	Gallagher78	Cancer	12	6	30	GPL570
Chronic	GSE100281	Willis-Owen79	COPD	80	15	85	GPL11532
Total				477	180	657
Secondary validation
MND	EMEXP3260	Pradat7	ALS	9	10	19	GPL96
MND	GSE3307	Bakay51	ALS	9	13c	22c	GPL96
CP	GSE31243	Smith80	CP	20	20	40	GPL570
Total				38	43	81

IM inflammatory myositides, MMD myotonic muscular dystrophy, MD muscular dystrophies, DMD Duchene’s muscular dystrophy, FSHD fascioscapulohumoral muscular dystrophy, LGMD2A limb-girdle muscular dystrophy type 2A, HIBM heritable IBM, POLG1, MD, TMD tibial muscular dystrophy, IBM inclusion body myositis, DM diabetes mellitus, GSD II glycogen storage disease type II, also called Pompe disease, POLG1 mitochondrial DNA polymerase γ, ICUAW intensive care unit acquired weakness, MODS multi-organ dysfunction syndrome.

^aNot published yet.

^bDeltoid muscle samples removed as FSHD typically affects biceps.

^cSame healthy controls used in subcohorts of GSE3307.